Market Place
Sourcing Support
Oragenics Doses First Patient in Ph IIa Clinical Trial of ONP-002
13 Apr 2026 //
GLOBENEWSWIRE
Oragenics Gets Audit Opinion With Going Concern Note
25 Mar 2026 //
GLOBENEWSWIRE
Oragenics Files Annual Report on Form 10-K
17 Mar 2026 //
GLOBENEWSWIRE
Oragenics Initiates Phase IIa Clinical Trial Site Activation
12 Mar 2026 //
GLOBENEWSWIRE
Oragenics Targets CNS Expansion in Brain Health
11 Mar 2026 //
GLOBENEWSWIRE
Oragenics Receives HREC Approval for Phase IIa Trial of ONP-002
10 Mar 2026 //
GLOBENEWSWIRE
Oragenics Advances Clinical-Stage Therapy For Concussion,
09 Feb 2026 //
GLOBENEWSWIRE
Oragenics to Participate in SCOPE Summit 2026
02 Feb 2026 //
GLOBENEWSWIRE
Oragenics Resolves NYSE American Compliance, Fixes Stockholder
21 Oct 2025 //
PHARMIWEB
Oragenics Partners With Receptor.Ai To Speed Up Development
07 Oct 2025 //
PHARMIWEB
Oragenics Q2 2025 Shareholder News
11 Aug 2025 //
GLOBENEWSWIRE
Oragenics Picks Southern Star for ONP-002 Ph IIa Trial Research
31 Jul 2025 //
GLOBENEWSWIRE
Oragenics Inks US Drug Manufacturing Deal for ONP-002 Development
16 Jul 2025 //
GLOBENEWSWIRE
Oragenics Completes Approximately $16.5 Million Offering
02 Jul 2025 //
GLOBENEWSWIRE
Oragenics to Present at 2025 BIO International Convention
10 Jun 2025 //
GLOBENEWSWIRE
Oragenics Announces One-for-Thirty Reverse Stock Split
28 May 2025 //
GLOBENEWSWIRE
Oragenics Gets Green Light for Phase II Concussion Trial
13 May 2025 //
GLOBENEWSWIRE
Oragenics to Host Management Update Webinar on May 20, 2025
12 May 2025 //
GLOBENEWSWIRE
Oragenics at 15th Annual Traumatic Brain Injury Conference
23 Apr 2025 //
GLOBENEWSWIRE
Oragenics Submits Phase IIa Concussion Trial to Ethics Committee
09 Apr 2025 //
GLOBENEWSWIRE
Oragenics, Inc. Joins 3rd Nasal Formulation & Delivery Summit
07 Apr 2025 //
GLOBENEWSWIRE
Oragenics Submits Brochure For Ph2 ONP-002 In mTBI Brain Injury
06 Mar 2025 //
GLOBENEWSWIRE
Oragenics CMO to Present at Emergencies in Medicine Conference
25 Feb 2025 //
GLOBENEWSWIRE
Oragenics CMO, Dr. James Kelly, Joins Leigh Steinberg Found
24 Feb 2025 //
GLOBENEWSWIRE
Oragenics Partners with BRAINBox for Concussion Treatment
11 Feb 2025 //
GLOBENEWSWIRE
Oragenics CMO Dr. James to Join 12th Annual Brain Health Summit
05 Feb 2025 //
GLOBENEWSWIRE
Oragenics Provides Strategic Update & Appoints Janet as CEO
21 Jan 2025 //
GLOBENEWSWIRE
Oragenics Announces Conversion of Preferred Shares, Liquidation
16 Dec 2024 //
GLOBENEWSWIRE
Oragenics, Inc. To Present At Centurion Bahamas Summit
18 Oct 2024 //
GLOBENEWSWIRE
Oragenics Completes Key FDA-Recognized Study For ONP-002
08 Oct 2024 //
GLOBENEWSWIRE
Oragenics, Inc. Announces Closing of Public Offering
05 Sep 2024 //
GLOBENEWSWIRE
Oragenics, Inc. Announces Pricing of Public Offering
04 Sep 2024 //
GLOBENEWSWIRE
Oragenics Project to Develop a Variant-Agnostic Protein Antigen
05 Jun 2023 //
BUSINESSWIRE
Oragenics to Participate in the World Vaccine Congress Washington
29 Mar 2023 //
BUSINESSWIRE
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax
01 Mar 2023 //
BUSINESSWIRE
